These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 433362)

  • 1. [Pharmacology of oral anticoagulants].
    Richter M; Markwardt F
    Z Gesamte Inn Med; 1979 Jan; 34(1):8-17. PubMed ID: 433362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological study of a new antivitamin K anticoagulant 3-(alpha-acetonylbenzyl) 4-hydroxycoumarin dimethylaminoethanol. (100 cases)].
    Migne J; Monteil R; Pessereau G; Pernod J; Siau J
    Therapie; 1968; 23(3):553-66. PubMed ID: 5740621
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anticoagulant of indirect action nitropharin].
    Lakin KM; Smirnova TV; Karaseva MG
    Farmakol Toksikol; 1968; 31(2):184-7. PubMed ID: 5674673
    [No Abstract]   [Full Text] [Related]  

  • 5. Vitamin K--dependent clotting factors.
    Prydz H
    Semin Thromb Hemost; 1977; 4(1):1-14. PubMed ID: 335512
    [No Abstract]   [Full Text] [Related]  

  • 6. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients.
    Xi M; Béguin S; Hemker HC
    Thromb Haemost; 1989 Sep; 62(2):788-91. PubMed ID: 2814925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
    Raby C
    Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756
    [No Abstract]   [Full Text] [Related]  

  • 8. [Vitamin K dependent blood clotting proteins (author's transl)].
    Kopeć M
    Postepy Biochem; 1980; 26(1):3-28. PubMed ID: 6994082
    [No Abstract]   [Full Text] [Related]  

  • 9. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
    Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
    Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of anticoagulants: correlation between the inhibition of prothrombin synthesis and the regeneration of vitamin K1 from vitamin K1 epoxide.
    Ren P; Stark PY; Johnson RL; Bell RG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):541-6. PubMed ID: 864593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of warfarin on the kinetics of the vitamin K-dependent clotting factors in rats.
    Vainieri H; Wingard LB
    J Pharmacol Exp Ther; 1977 May; 201(2):507-17. PubMed ID: 870684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
    Makris M; Greaves M; Phillips WS; Kitchen S; Rosendaal FR; Preston EF
    Thromb Haemost; 1997 Mar; 77(3):477-80. PubMed ID: 9065997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of action of oral anticoagulants].
    Uszyński L
    Acta Haematol Pol; 1972; 3(2):133-9. PubMed ID: 4655612
    [No Abstract]   [Full Text] [Related]  

  • 14. Release of vitamin K-dependent coagulation factors by isolated perfused rat liver.
    Kazmier FJ; Spittell JA; Bowie EJ; Thompson JH; Owen CA
    Am J Physiol; 1968 Apr; 214(4):919-22. PubMed ID: 5651226
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin K and warfarin. Metabolism, function and interaction.
    Woolf IL; Babior BM
    Am J Med; 1972 Sep; 53(3):261-7. PubMed ID: 5054720
    [No Abstract]   [Full Text] [Related]  

  • 16. The pharmacology of oral anticoagulants: implications for therapy.
    Shetty HG; Woods F; Routledge PA
    J Heart Valve Dis; 1993 Jan; 2(1):53-62. PubMed ID: 8269110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of liver maintenance of normal hemostasis].
    Rosiek B
    Pol Tyg Lek; 1974 Jun; 30(22):949-52. PubMed ID: 4601065
    [No Abstract]   [Full Text] [Related]  

  • 18. Half-life time and control frequency of vitamin K-dependent Coagulation factors. Theoretical considerations on the place of factor VII in the control of oral anticoagulation therapy.
    van Dam-Mieras MC; Hemker HC
    Haemostasis; 1983; 13(3):201-8. PubMed ID: 6350124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
    van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
    Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anticoagulation by oral treatment with vitamin K antagonists].
    Kemkes-Matthes B
    Hamostaseologie; 2008 Dec; 28(5):421-7. PubMed ID: 19132171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.